Market Overview

Teva's 'Achievable' 2018 Outlook, Restructuring Plan Trigger Credit Suisse Upgrade

Teva's 'Achievable' 2018 Outlook, Restructuring Plan Trigger Credit Suisse Upgrade
Related TEVA
Benzinga's Top Upgrades, Downgrades For January 3, 2019
The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced a restructuring program late last year that is now showing some signs of early success, according to Credit Suisse.

The Analyst

Credit Suisse's Vamil Divan upgraded Teva's stock rating from Neutral to Outperform with a price target boosted from $20 to $23.

The Thesis

Teva's initial restructuring plan prompted Divan to upgrade Teva's stock rating from Underperform, but now that more details on the plan have been made, a bullish stance is warranted, he said. (See the analyst's track record here.) 

Teva's 2018 outlook looks "achievable," even though it includes the potential impact of a second generic Copaxone 40mg coming to the U.S. market in the coming months, Divan said. 

A potential delay to Teva's migraine therapy was "generally expected," but the market for migraine treatments is large enough for multiple blockbusters, even if Teva is fourth to the market, the analyst said. 

In addition, the Israel-based company's move to hire Kare Schultz as CEO is encouraging, as he boasts a "positive track record" of overseeing turnarounds at pharmaceutical giants, according to Credit Suisse. 

The generics industry as a whole is expected to see continued volatility, with stabilization in 2019 and beyond, Divan said. Teva's sell-off and business reset creates a reasonable near-term expectation that clears a path for upside in the stock, he said. 

Price Action

Shares of Teva were trading higher by 2.3 percent after the open Monday. 

Related Links:

Teva's Cost-Cutting Plan Nets A Mizuho Upgrade

Teva Vs Mylan: Wells Fargo Weighs In

Latest Ratings for TEVA

Jan 2019Bank of AmericaUpgradesUnderperformBuy
Nov 2018Morgan StanleyUpgradesEqual-WeightOverweight
Nov 2018Bank of AmericaMaintainsUnderperformUnderperform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Copaxone Credit Suisse Generics israelAnalyst Color Upgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (TEVA)

View Comments and Join the Discussion!

Latest Ratings

CNPRBC CapitalUpgrades34.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

7 Biggest Price Target Changes For Monday

Rosenblatt: Comcast Challenge For Fox Assets Could Reduce Arbitrage Discount